Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs,...

Full description

Bibliographic Details
Main Authors: Andreas Blesl, Elisabeth Krones, Marion J. Pollheimer, Johannes Haybaeck, Ulrike Wiesspeiner, Rainer W. Lipp, Patrizia Kump
Format: Article
Language:English
Published: Karger Publishers 2017-12-01
Series:Case Reports in Oncology
Subjects:
Neuroendocrine tumor
Chemotherapy
Liver biopsy
mTor
Somatostatin
Online Access:https://www.karger.com/Article/FullText/484473
id doaj-7f7e835f224b496d97094ec9e1a27ac9
record_format Article
spelling doaj-7f7e835f224b496d97094ec9e1a27ac92020-11-24T21:06:44ZengKarger PublishersCase Reports in Oncology1662-65752017-12-011031121112610.1159/000484473484473Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?Andreas BleslElisabeth KronesMarion J. PollheimerJohannes HaybaeckUlrike WiesspeinerRainer W. LippPatrizia KumpThe antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.https://www.karger.com/Article/FullText/484473Neuroendocrine tumorChemotherapyLiver biopsymTorSomatostatin
collection DOAJ
language English
format Article
sources DOAJ
author Andreas Blesl
Elisabeth Krones
Marion J. Pollheimer
Johannes Haybaeck
Ulrike Wiesspeiner
Rainer W. Lipp
Patrizia Kump
spellingShingle Andreas Blesl
Elisabeth Krones
Marion J. Pollheimer
Johannes Haybaeck
Ulrike Wiesspeiner
Rainer W. Lipp
Patrizia Kump
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Case Reports in Oncology
Neuroendocrine tumor
Chemotherapy
Liver biopsy
mTor
Somatostatin
author_facet Andreas Blesl
Elisabeth Krones
Marion J. Pollheimer
Johannes Haybaeck
Ulrike Wiesspeiner
Rainer W. Lipp
Patrizia Kump
author_sort Andreas Blesl
title Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_short Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_full Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_fullStr Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_full_unstemmed Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_sort downgrading of a g3 neuroendocrine tumor to a g2 tumor: can first-line cytotoxic chemotherapy change the tumor biology?
publisher Karger Publishers
series Case Reports in Oncology
issn 1662-6575
publishDate 2017-12-01
description The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.
topic Neuroendocrine tumor
Chemotherapy
Liver biopsy
mTor
Somatostatin
url https://www.karger.com/Article/FullText/484473
work_keys_str_mv AT andreasblesl downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT elisabethkrones downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT marionjpollheimer downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT johanneshaybaeck downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT ulrikewiesspeiner downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT rainerwlipp downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT patriziakump downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
_version_ 1716764911190671360

Similar Items